Attgeno is a pharmaceutical company based in Stockholm, Sweden.
The company is developing a novel nitric oxide donor called Supernitro for the treatment of acute pulmonary hypertension caused by cardiovascular or pulmonary diseases. Supernitro will be the first and only intravenous drug to selectively treat acute high blood pressure in the lungs
YEAR OF INVESTMENT
2018
SECTOR
Drug development
LOCATION
Stockholm, Sweden
WEBSITE
https://attgeno.com/
The company is developing a novel nitric oxide donor called Supernitro for the treatment of acute pulmonary hypertension caused by cardiovascular or pulmonary diseases. Supernitro will be the first and only intravenous drug to selectively treat acute high blood pressure in the lungs
YEAR OF INVESTMENT
2018
SECTOR
Drug development
LOCATION
Stockholm, Sweden
WEBSITE
https://attgeno.com/
Investors 2
| Date | Name | Website |
| - | Hadean Ven... | hadeanvent... |
| - | Eir Ventur... | eirventure... |
Mentions in press and media 3
| Date | Title | Description |
| 08.07.2025 | OncoZenge Appoints Tuulikki Lindmark as Head of CMC in Phase 3 Sponsor Team | OncoZenge Appoints Tuulikki Lindmark as Head of CMC in Phase 3 Sponsor Team Tue, Jul 08, 2025 10:00 CET Report this content OncoZenge AB (publ) ("OncoZenge" or "the Company") announces today that the sponsor team for the... |
| 08.07.2021 | Attgeno appoints Björn Westberg as CFO | Attgeno AB announces today that Björn Westberg has been appointed CFO and member of the management team at Attgeno. Björn most recently comes from a role as CFO at Enea AB (publ). Björn has extensive experience in the Life Science sector... |
| 25.03.2021 | French biotech company Step Pharma raises €35 million in Series B | Step Pharma, a Paris based biotech company, announced on 24th March 2021 that it has raised €35 million in its Series B funding round. The round was led by Sunstone Life Science Ventures and Hadean Ventures, along with participation from Ku... |